证 券 研 究 报 告 公 司 报 告 2024年08月27日 医药 强烈推荐( 维持) 事项： 平安观点： 行情走势图 主要数据 | --- | --- | |-------------------|---------------------------------| | 行业 | 医药 | | 公司网址 | www.yuwell.com | | 大股东/持股 | 江苏鱼跃科技发展有限公司/24.54% | | 实际控制人 | 吴光明 | | 总股本(百万股) | 1,002 | | 流通A股(百万股) | 939 | | 流通B/H股(百万股) | | | 总市值(亿元) | 327 | | 流通A股市值(亿元) | 306 | | 每股净资产(元) | 12.07 | | 资产负债率(%) | 21.5 | 叶寅 投资咨询资格编号 倪亦道 投资咨询资格编号 裴晓鹏 投资咨询资格编号 S1060523090002 PEIXIAOPENG719@pingan.com.cn S1060514100001 BOT335 YEYIN757@pingan.com.cn S1060518070001 021-3864 ...

证券研究报告 医药生物 证券分析师 刘闯 S1350524030002 liuchuang@huayuanstock.com 市场表现： -20% -10% 0% 10% 20% 30% 鱼跃医疗 沪深300 相关研究 1.《鱼跃医疗（002223.SZ）：创新 重塑成长，家用器械平台龙头焕发新 活力》，2024.05.13 股价数据： 2024 年 8 月 25 日 收盘价（元） 34.09 年内最高/最低（元） 41.8/31.69 总市值（亿元） 342 公司点评 2024 年 8 月 27 日 鱼跃医疗（002223.SZ） 买入（维持） ——血糖等常规品种表现较好，海外显著提速 投资要点： ➢ 公司事件：鱼跃医疗发布 2024 年中期业绩公告，2024 上半年实现营收 43.1 亿元（同比 -13.5%）；归母净利润 11.2 亿元（同比-25.0%），扣非归母净利润 9.6 亿元（同比-23.2%）； 24Q2 单季度实现营收 20.8 亿元（同比-8.8%）；归母净利润 4.6 亿元（同比-41.0%），扣 非归母净利润 4.1 亿元（同比-25.1%）。 ➢ 高基数下业绩承压，血糖等常规品种表 ...

Group 1: Blood Glucose Management - The diabetes care segment has shown significant development, with a focus on enhancing product competitiveness and marketing strategies to increase market share [3][4]. - The company aims to leverage brand advantages and expand its presence in both domestic and international markets, establishing a strong professional endorsement for its blood glucose products [4]. Group 2: Emergency Response Products - The emergency response segment achieved a revenue growth of 34.66% in the first half of 2024, with a steady increase in gross margin [4]. - The company is optimistic about the future of this segment, focusing on product registration and market expansion, particularly with the introduction of higher-margin new products [4]. Group 3: Respiratory Therapy Products - The respiratory therapy segment, including oxygen machines and nebulizers, has seen steady growth, with double-digit sales increases compared to the previous year [5]. - The company recognizes the growing demand for respiratory products due to an aging population and is committed to expanding its product offerings in both domestic and international markets [5][6]. Group 4: Home Electronic Testing Products - The home electronic testing segment reported revenue of 935 million yuan in the first half of the year, showing a slight decline due to high demand in previous years [5]. - Despite some product declines, the electronic blood pressure monitor remains a key category with steady growth, supported by new product launches and market expansion efforts [5]. Group 5: Marketing and Sales Strategies - The company has adjusted its marketing strategies in response to market conditions, with increased investments in key products and promotional activities [6]. - The overall performance in the out-of-hospital market has improved, with both online and offline sales returning to normal rhythms and new products successfully launched [6]. Group 6: Future Plans and Mergers - The company plans to extend its successful domestic distribution strategies to overseas markets, focusing on building robust service systems to meet customer needs [6]. - There is ongoing interest in potential mergers and acquisitions to enhance growth and shareholder value, with careful evaluation of opportunities aligned with long-term strategies [6].

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-029 一、召开会议的基本情况 江苏鱼跃医疗设备股份有限公司 （一）股东大会届次：2024年第一次临时股东大会； 关于召开 2024 年第一次临时股东大会的通知 （二）会议的召集人：公司董事会； （三）会议召开的合法、合规性：本次股东大会的召开符合《中华人民共和 国公司法》《上市公司股东大会规则》等法律、法规、规范性文件及《江苏鱼跃 医疗设备股份有限公司章程》的有关规定。 （四）会议召开时间： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）第 六届董事会第三次会议提请，公司将于2024年9月9日召开2024年第一次临时股东 大会，现就本次股东大会相关事项通知如下： 1、现场会议时间：2024年9月9日下午13:30 通过深圳证券交易所交易系统进行网络投票的时间为2024年9月9日 9:15~9:25，9:30~11:30，13:00~15:00； 通过深圳证券交易所互联网投票系统投票的时间为2024年9月9日上午9:15 至下午3: ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-025 江苏鱼跃医疗设备股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 2024 年 8 月 23 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）以通讯表 决的方式召开了第六届董事会第三次会议。公司于 2024 年 8 月 13 日以书面送达及电子 邮件方式向公司全体董事发出了召开公司第六届董事会第三次会议的通知以及提交审 议的议案。会议应出席董事 9 名，实际出席会议董事 9 名。本次会议的召集、召开及表 决等程序符合《中华人民共和国公司法》和《公司章程》的有关规定，会议决议合法、 有效。会议由董事长吴群先生主持，经与会董事充分讨论，审议通过了如下议案： 二、董事会会议审议情况 1、关于《公司 2024 年半年度报告及其摘要》的议案 本议案需提交公司 2024 年第一次临时股东大会审议。 本议案中公司 2024 年半年度财务报表已经公司董事会审计委员会审议通过。 《江苏鱼跃医疗设备股份有限公司 2024 年半年度报告》全 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-028 江苏鱼跃医疗设备股份有限公司 关于公司 2024 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 23 日召开第六届董事会第三次会议、第六届监事会第三次会议，审议通 过了关于《公司 2024 年半年度利润分配预案》的议案，该议案尚需提交 2024 年 第一次临时股东大会审议，现将该分配预案的具体情况公告如下： 一、公司 2024 年半年度利润分配预案情况 二、监事会意见 监事会认为：经审核，公司 2024 年半年度利润分配预案符合相关法律、法 规以及《公司章程》的规定，兼顾了投资者的利益和公司持续发展的资金需求， 同意该利润分配预案。 三、其他说明 1、本次利润分配预案需经股东大会审议通过后方可实施，存在不确定性， 敬请广大投资者理性投资，注意投资风险； 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年 1-6 月税后利 润（母公司）为人民币 788,305 ...

江苏鱼跃医疗设备股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用 方名称 | 占用方与 上市公司 的关联关 | 上市公司核 算的会计科 | 2024 年期初 占用资金余 | 2024 年 1-6 月占用累计 发生金额 | 2024 年 1- 6 月占用资 金的利息 | 2024 年 1-6 月偿还累计 | 2024 年 6 月 30 日占 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 系 | 目 | 额 | （不含利 | （如有） | 发生金额 | 用资金余额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | | | ...

江苏鱼跃医疗设备股份有限公司 第六届监事会第三次会议决议公告 证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-026 2、关于《公司2024年半年度利润分配预案》的议案 表决结果：同意：7 票；反对：0 票；弃权：0 票 1 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江苏鱼跃医疗设备股份有限公司（以下简称"公司"）于 2024 年 8 月 13 日 以书面送达及电子邮件形式向公司全体监事发出了召开公司第六届监事会第三 次会议的通知。会议于 2024 年 8 月 23 日以通讯表决的方式召开，会议应到监事 7 人，实到监事 7 人。本次会议的召集、召开符合《中华人民共和国公司法》和 《公司章程》的有关规定，会议决议合法、有效。会议由公司监事会主席吕英芳 先生主持，经与会监事充分讨论，审议通过了如下议案： 二、监事会会议审议情况 1、关于《公司2024年半年度报告及其摘要》的议案 表决结果：同意：7票；反对：0票；弃权：0票 监事会认为：董事会编制和审议《江苏鱼跃医疗设备股份有限公司2024年半 年度报告及其摘要》的程 ...

Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period is 41,848[91] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of the shares, totaling 245,983,450 shares[91] - Wu Guangming holds 10.32% of the shares, totaling 103,438,537 shares[91] - Wu Qun holds 7.72% of the shares, totaling 77,389,840 shares[91] - Hong Kong Securities Clearing Company Ltd. holds 3.49% of the shares, totaling 35,021,001 shares[91] - China Bank - Huabao CSI Medical ETF holds 1.93% of the shares, totaling 19,318,094 shares[91] - China Everbright Bank - Xingquan Business Model Preferred Hybrid Fund holds 1.32% of the shares, totaling 13,243,042 shares[91] - Industrial Bank - Xingquan New Vision Flexible Allocation Fund holds 1.11% of the shares, totaling 11,078,650 shares[91] - Basic Pension Fund 802 Portfolio holds 1.00% of the shares, totaling 10,000,007 shares[91] - National Social Security Fund 113 Portfolio holds 0.91% of the shares, totaling 9,169,229 shares[91] Financial Performance - Total assets decreased from 15,967,458,083.34 yuan to 15,616,627,078.76 yuan, a decrease of 2.2%[100] - Cash and cash equivalents decreased from 7,215,419,322.83 yuan to 6,566,988,527.29 yuan, a decrease of 9.0%[99] - Accounts receivable increased significantly from 448,210,952.92 yuan to 1,109,191,401.44 yuan, a 147.5% increase[99] - Inventory decreased from 1,412,311,882.61 yuan to 1,239,219,309.04 yuan, a decrease of 12.3%[99] - Total liabilities decreased from 4,051,960,445.73 yuan to 3,359,372,945.56 yuan, a decrease of 17.1%[100] - Long-term equity investments decreased from 225,884,423.71 yuan to 63,977,361.43 yuan, a decrease of 71.7%[100] - Fixed assets increased slightly from 1,974,016,723.76 yuan to 2,001,724,995.64 yuan, a 1.4% increase[100] - Retained earnings increased from 8,412,104,595.40 yuan to 8,730,698,539.15 yuan, a 3.8% increase[101] - Short-term borrowings decreased from 274,896,028.80 yuan to 387,886,638.31 yuan, a 41.1% increase[100] - Total equity increased from 11,915,497,637.61 yuan to 12,257,254,133.20 yuan, a 2.9% increase[101] - Total revenue for the first half of 2024 decreased to 4,307,611,897.68 RMB from 4,979,904,160.12 RMB in the same period of 2023, representing a decline of approximately 13.5%[105] - Net profit for the first half of 2024 was 1,122,893,792.17 RMB, down from 1,481,490,935.07 RMB in the first half of 2023, a decrease of about 24.2%[106] - Total assets as of the end of the first half of 2024 were 15,004,870,740.15 RMB, slightly lower than the 15,370,544,619.54 RMB at the end of the first half of 2023[103][104] - Total liabilities increased to 4,013,548,739.91 RMB in the first half of 2024 from 4,389,183,483.67 RMB in the same period of 2023[103][104] - Research and development expenses for the first half of 2024 were 269,617,925.64 RMB, a slight decrease from 273,681,234.77 RMB in the first half of 2023[105] - Operating profit for the first half of 2024 was 1,288,049,438.08 RMB, down from 1,797,530,327.47 RMB in the first half of 2023, a decline of approximately 28.3%[106] - Total equity attributable to shareholders was 10,991,322,000.24 RMB at the end of the first half of 2024, compared to 10,981,361,135.87 RMB at the end of the first half of 2023[104] - Interest income for the first half of 2024 increased significantly to 115,157,364.09 RMB from 56,346,593.12 RMB in the same period of 2023[106] - Other income for the first half of 2024 was 178,451,529.82 RMB, up from 60,597,376.77 RMB in the first half of 2023[106] - Total current assets as of the end of the first half of 2024 were 7,887,888,767.18 RMB, slightly lower than the 8,065,843,771.44 RMB at the end of the first half of 2023[103] - Operating revenue for the first half of 2024 was 2.96 billion yuan, a decrease of 15.0% compared to 3.49 billion yuan in the same period last year[108] - Net profit for the first half of 2024 was 788.31 million yuan, a decrease of 8.0% compared to 857.18 million yuan in the same period last year[109] - Basic earnings per share for the first half of 2024 was 1.1244 yuan, a decrease of 25.3% compared to 1.5046 yuan in the same period last year[107] - R&D expenses for the first half of 2024 were 123.89 million yuan, a decrease of 22.2% compared to 159.29 million yuan in the same period last year[108] - Net cash flow from operating activities for the first half of 2024 was 1.01 billion yuan, a decrease of 32.4% compared to 1.50 billion yuan in the same period last year[110] - Sales revenue from goods and services for the first half of 2024 was 3.94 billion yuan, a decrease of 20.0% compared to 4.93 billion yuan in the same period last year[110] - Total comprehensive income for the first half of 2024 was 1.12 billion yuan, a decrease of 24.6% compared to 1.49 billion yuan in the same period last year[107] - Interest income for the first half of 2024 was 89.91 million yuan, an increase of 88.5% compared to 47.70 million yuan in the same period last year[108] - Other income for the first half of 2024 was 162.06 million yuan, an increase of 729.2% compared to 19.55 million yuan in the same period last year[108] - Foreign exchange translation difference for the first half of 2024 was 142,688.72 yuan, a decrease of 97.8% compared to 6.39 million yuan in the same period last year[107] - Investment activities cash outflow totaled 151.33 million yuan, a significant decrease from 1.79 billion yuan in the previous period[111] - Net cash flow from investment activities was 133.43 million yuan, down from 244.41 million yuan in the previous period[111] - Net cash flow from financing activities was -1.79 billion yuan, compared to -1.60 billion yuan in the previous period[111] - Cash and cash equivalents at the end of the period were 6.55 billion yuan, down from 7.19 billion yuan at the beginning of the period[111] - Sales revenue from goods and services was 2.60 billion yuan, a decrease from 3.73 billion yuan in the previous period[112] - Net cash flow from operating activities was 1.01 billion yuan, down from 1.58 billion yuan in the previous period[112] - Net cash flow from investment activities was -33.60 million yuan, compared to 276.56 million yuan in the previous period[113] - Net cash flow from financing activities was -1.65 billion yuan, compared to -1.48 billion yuan in the previous period[113] - Cash and cash equivalents at the end of the period were 5.99 billion yuan, down from 6.66 billion yuan at the beginning of the period[113] - Comprehensive income for the period was 1.12 billion yuan, contributing to the increase in owner's equity[115] - The company's capital reserve increased by 1,143,081.00 yuan in the current period, with a usage of 185,935.61 yuan, resulting in a net increase of 957,145.39 yuan[116] - The company's comprehensive income for the current period amounted to 6,394,245.91 yuan, contributing to a total comprehensive income of 1,500,412,381.74 yuan[118] - The company's owner's equity at the end of the period was 10,977,399,806.92 yuan, reflecting an increase from the beginning balance of 10,066,485,523.85 yuan[119] - The company's capital reserve saw an increase of 10,927,155.33 yuan due to owner's contributions and other equity tool holders' capital[118] - The company's profit distribution to owners (or shareholders) amounted to 597,748,057.20 yuan[119] - The company's special reserve for the current period was 1,543,355.10 yuan, with an extraction of 1,801,658.70 yuan and a usage of 258,303.60 yuan[119] - The company's other comprehensive income for the current period was -3,126,092.05 yuan, which was offset by a gain of 6,394,245.91 yuan[118] - The company's retained earnings at the end of the period were 7,510,322,405.74 yuan, up from 6,614,052,327.11 yuan at the beginning of the period[119] - The company's total owner's equity at the end of the period was 10,977,399,806.92 yuan, compared to 10,066,485,523.85 yuan at the beginning of the period[119] - The company's capital reserve at the end of the period was 2,000,189,502.09 yuan, up from 1,989,262,346.76 yuan at the beginning of the period[119] - Total comprehensive income for the period reached RMB 788.31 million[121] - Capital reserve increased by RMB 19.90 million due to owner contributions[121] - Profit distribution to owners amounted to RMB 801.60 million[121] - Comprehensive income for the period was RMB 857.18 million[124] - Owner contributions and capital reduction resulted in an increase of RMB 10.93 million[124] - Profit distribution to owners was RMB 597.75 million[124] - Total equity at the end of the period was RMB 10.99 billion[122] - Total equity at the end of the period was RMB 9.53 billion[125] Company Overview - The company was established in 1998 and went public in 2008[126] - Total share capital of the company is 1,002,476,929 shares, with public shares accounting for 56.2031% (563,424,319 shares)[127] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.5376% of the shares (245,983,450 shares)[127] - The company has 48 subsidiaries consolidated in the first half of 2024[128] - A new subsidiary, Shanghai Lisi Jie Health Technology Co., Ltd., was added in May-June 2024[129] - The company operates in the medical device manufacturing industry, with business segments including diabetes management, emergency care, and surgical instruments[128] - The company's financial statements are prepared in accordance with Chinese Accounting Standards and CSRC regulations[132] - The company has a 12-month operating cycle and uses RMB as its functional currency[136] - The company's accounting policies include specific methods for bad debt provision, inventory measurement, and revenue recognition[134] - The company has established a new subsidiary in the US, Yuyue Medical Technology LLC, added in March-June 2024[130] - The company's financial statements reflect no significant concerns regarding its ability to continue as a going concern for the next 12 months[133] Significant Financial Events - Significant bad debt provision for receivables: Single provision amount exceeds 5% of total bad debt provision for receivables and is greater than 20 million RMB[137] - Significant recovery or reversal of bad debt provision for receivables: Single recovery or reversal amount exceeds 5% of total bad debt provision for receivables and is greater than 20 million RMB[137] - Significant write-off of receivables: Single write-off amount exceeds 5% of total bad debt provision for receivables and is greater than 20 million RMB[137] - Significant R&D projects expensed or externally acquired: Single R&D project budget exceeds 2% of total R&D expenses and is greater than 10 million RMB[137] - Significant construction in progress: Single project budget exceeds 100 million RMB[137] - Significant investment activities: Single investment activity exceeds 10% of total cash inflows or outflows related to investment activities and is greater than 100 million RMB[137] - Significant joint ventures or associates: Long-term equity investment in a single investee exceeds 2% of group net assets and is greater than 50 million RMB, or investment income under equity method exceeds 5% of group consolidated net profit[137] - Significant subsidiaries: Subsidiary net assets exceed 5% of group net assets, or subsidiary total profit exceeds 10% of group consolidated total profit[137] - Significant contract liabilities: Single contract liability aged over 1 year exceeds 10% of total contract liabilities and is greater than 10 million RMB[137] - Significant accounts payable: Single account payable aged over 1 year exceeds 5% of total accounts payable and is greater than 30 million RMB[137] Financial Assets and Liabilities - The company's financial assets are initially measured at fair value, with transaction costs directly recognized in profit or loss for those classified as fair value through profit or loss, while other categories include transaction costs in their initial recognition amount[144] - Financial assets classified as amortized cost include cash, accounts receivable, notes receivable, and other receivables, managed under a business model aimed at collecting contractual cash flows[144] - Financial assets classified as fair value through other comprehensive income (FVOCI) include debt instruments managed under a business model that aims to both collect contractual cash flows and sell the financial assets[144] - The company irrevocably designates certain non-trading equity investments as FVOCI, with subsequent fair value changes recognized in other comprehensive income and no impairment provisions required[144] - Financial liabilities are classified as either fair value through profit or loss or amortized cost, with transaction costs recognized accordingly[144] - The company uses an expected credit loss model to assess impairment for financial assets and contract assets, considering historical repayment data, economic policies, and macroeconomic indicators[145] - Accounts receivable and contract assets are grouped based on credit risk characteristics such as aging, nature of receivables, and historical repayment patterns[145] - For accounts receivable within the consolidated group, the company considers the actual performance and historical repayment of related parties, with no bad debt provision required due to low credit risk[146] - The company assesses expected credit losses for notes receivable based on the credit risk of the acceptor, with no expected credit loss recognized for bank acceptance notes from listed commercial banks[147] - The company evaluates bank acceptance bills as having no significant credit risk and does not need to provide for bad debts[148] - Commercial acceptance bills are subject to bad debt provisions based on expected credit losses, similar to accounts receivable[148] - Other receivables are categorized into different groups based on credit risk, with some groups requiring no bad debt provisions due to low credit risk[149] - Long-term receivables are measured for expected credit losses based on the credit risk increase since initial recognition[149] - Financial asset transfers are recognized and measured based on the transfer of risks and rewards, with differences in book value and consideration received recorded in current profit or loss[150] - Financial liabilities and equity instruments are distinguished based on the company's obligation to deliver cash or other financial assets[150] - Financial assets and liabilities are presented separately in the balance sheet unless specific conditions for offsetting are met[150] - Accounts receivable are treated similarly to financial assets measured at amortized cost[151] - Receivables financing is treated similarly to debt instrument investments measured at fair value with changes in other comprehensive income[152] - Contract assets represent the right to receive consideration for goods transferred to customers, contingent on factors other than the passage of time[153] - Non-current assets held for sale are not depreciated or amortized, and interest and other expenses on liabilities within disposal groups held for sale continue to be recognized[156] - The company measures long-term receivables' expected credit losses based on three scenarios: 1) financial assets with no significant increase in credit risk since initial recognition, 2) financial assets with a significant increase in credit risk since initial recognition, and 3) purchased or originated financial assets that have already experienced credit impairment[157] - The company's long-term equity investments include investments in subsidiaries and associates, with significant influence typically assumed when the company holds between 20% and 50% of the voting rights[158] - The company uses the equity method to account for investments in joint ventures and associates, adjusting the carrying amount of the investment based on changes in the investee's net assets[159] - Investment properties are measured using the cost model, with land use rights depreciated over 50 years and buildings depreciated over 20 years with a 5% residual value[160] - The company defines fixed assets as tangible assets held for production, service provision, rental, or management purposes, with a useful life exceeding one year and a unit value exceeding 2000 RMB[161] - Depreciation methods for buildings: straight-line method over 20-30 years with a residual value rate of 5% and annual depreciation rate of 3.17%-4.75%[162] - Depreciation methods for machinery: straight-line method over 5-20 years with a residual

证券代码：002223 证券简称：鱼跃医疗 公告编号：2024-024 江苏鱼跃医疗设备股份有限公司 关于转让产业投资基金份额的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、交易概述 1、江苏鱼跃医疗设备股份有限公司（以下简称"公司"、"鱼跃医疗"）于 2020 年 10 月 8 日召开了第四届董事会第二十七次临时会议，同意公司以自有资金人民币 20,000 万元作为有限合伙人参与投资设立无锡阿斯利康中金医疗创业投资合伙企业（有 限合伙）（以下简称"合伙企业"），并授权公司管理层办理合伙协议签署等相关事宜。 具体内容详见公司刊登于巨潮资讯网（www.cninfo.com.cn）及《证券时报》的《关于参 与投资设立阿斯利康中金医疗创业投资合伙企业（有限合伙）的公告》（公告编号：2020- 055）。 2、公司于 2024 年 8 月 16 日与康龙化成（北京）新药技术股份有限公司（以下简 称"康龙化成"）、中金私募股权投资管理有限公司（以下简称"中金私募"）及阿斯 利康商务咨询（无锡）有限公司（以下简称"阿斯利康"）签署了《关于无锡阿斯利康 中金创业 ...